The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats

Molecular Medicine Reports

Volumn 7, Issue 4, 2013, Pages 1267-1272

  Joo, Moon Kyung ^a   Park, Jong Jae ^a   Lee, Beom Jae ^a   Kim, Ji Hoon ^a   Yeon, Jong Eun ^a   Kim, Jae Seon ^a   Byun, Kwan Soo ^a   Bak, Young Tae ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bone metabolism; Osteoclast; Proton pump inhibitor

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; NUCLEAR FACTOR OF ACTIVATED T CELLS C1; OMEPRAZOLE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN C FOS; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LONG TERM CARE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; BONE AND BONES; BONE RESORPTION; CALCIUM; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HUMANS; OSTEOCLASTS; OSTEOPROTEGERIN; OVARIECTOMY; PROTON PUMP INHIBITORS; RANK LIGAND; RATS; SIGNAL TRANSDUCTION;

EID: 84875251798     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1327     Document Type: Article

References (32)

1. El-Serag HB: Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 5: 17-26, 2007.
2. DeVault KR and Castell DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100: 190-200, 2005.
3. Soll AH: Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 275: 622-629, 1996.
4. Talley NJ and Vakil N: Guidelines for the management of dyspepsia. Am J Gastroenterol 100: 2324-2337, 2005.
5. van Zanten SV, Armstrong D, Chiba N, et al: Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled 'ENTER' trial. Am J Gastroenterol 101: 2096-2106, 2006.
6. Becker V, Bajbouj M, Waller K, Schmid RM and Meining A: Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther 26: 1355-1360, 2007.
7. Dent J, Brun J, Fendrick A, et al: An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 44 (Suppl 2): S1-S16, 1999.
8. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH and Wang TC: Who is using chronic acid suppression therapy and why? Am J Gastroenterol 98: 51-58, 2003.
9. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S and Leslie WD: Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179: 319-326, 2008.
10. Yang YX, Lewis JD, Epstein S and Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296: 2947-2953, 2006.
11. Chonan O, Takahashi R, Yasui H and Watanuki M: Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol 44: 473-481, 1998.
12. O'Connell MB, Madden DM, Murray AM, Heaney RP and Kerzner LJ: Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118: 778-781, 2005.
13. Karsdal MA, Henriksen K, Sorensen MG, et al: Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166: 467-476, 2005.
14. Niikura K, Takeshita N and Takano M: A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res 20: 1579-1588, 2005.
15. Kocsis I, Arato A, Bodánszky H, et al: Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int 71: 129-132, 2002.
16. +,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53: 21-25, 1993.
17. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999.
18. Boyce BF and Xing L: Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473: 139-146, 2008.
19. Huang H, Ryu J, Ha J, et al: Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL. Cell Death Differ 13: 1879-1891, 2006.
20. Boyce BF and Xing L: The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5: 98-104, 2007.
21. Kwan Tat S, Pelletier JP, Lajeunesse D, Fahmi H, Lavigne M and Martel-Pelletier J: The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 26: 295-304, 2008.
22. Matsuo K, Galson DL, Zhao C, et al: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 279: 26475-26480, 2004.
23. Takayanagi H, Kim S, Koga T, et al: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901, 2002.
24. Yamashita T, Yao Z, Li F, et al: NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282: 18245-18253, 2007.
25. Lee BJ, Park JJ, Joo MK, et al: Effect of proton pump inhibitor on the bone turnover in the ovariectomized ICR mice. J Gastroenterol Hepatol 23 (Suppl 5): A10, 2008.
26. Niikura K, Takeshita N and Chida N: A novel inhibitor of vacuolar ATPase, FR202126, prevents alveolar bone destruction in experimental periodontitis in rats. J Toxicol Sci 30: 297-304, 2005.
27. Sorensen MG, Henriksen K, Schaller S and Karsdal MA: Biochemical markers in preclinical models of osteoporosis. Biomarkers 12: 266-286, 2007.
28. Cadir FO, Bicakci U, Tander B, et al: Protective effects of vitamin E and omeprazole on the hypoxia/reoxygenation induced intestinal injury in newborn rats. Pediatr Surg Int 24: 809-813, 2008.
29. Diogo Filho A, Santos PS, Duque AS, Cezário RC and Gontijo Filho PP: Experimental model in the qualitative and quantitative assessment of non-Helicobacter gastric microflora under proton pump inhibitors action. Acta Cir Bras 21: 279-284, 2006.
30. Elseweidy MM, Younis NN, Amin RS, Abdallah FR, Fathy AM and Yousif ZA: Effect of some natural products either alone or in combination on gastritis induced in experimental rats. Dig Dis Sci 53: 1774-1784, 2008.
31. Otomo H, Sakai A, Ikeda S, et al: Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. J Bone Miner Metab 22: 404-414, 2004.
32. Song YH, Lee W, Lee CJ, Ji JH and Lee BD: Study of bony trabecular characteristics using bone morphometry and micro-CT. Korean J Oral Maxillofac Radiol 37: 27-33, 2007.